Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2003
12/25/2003US20030235864 Method to screen ligands using eukaryotic cell display
12/25/2003US20030235861 Multimolecular, two-dimensional lattice or aggregate comprising immobilized cd antigens and monoclonal antibodies for monitor protein binding activity; competetive binding bioassay; treating cancer, allergies and inflammation
12/25/2003US20030235842 Map
12/25/2003US20030235835 Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
12/25/2003US20030235833 Guanosine triphosphate-binding protein coupled receptors
12/25/2003US20030235831 Nucleic acids, proteins, and antibodies
12/25/2003US20030235829 Nucleic acids, proteins, and antibodies
12/25/2003US20030235823 Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation
12/25/2003US20030235821 Novel Human proteins, polynucleotides encoding them and methods of using the same
12/25/2003US20030235612 Compounds and compositions for delivering active agents
12/25/2003US20030235611 Vesicle comprises ATP and phospholipid; fusion proteins
12/25/2003US20030235594 Comprises major histocompatability complex I epitopes
12/25/2003US20030235592 Moraxella catarrhalis protein, gene sequence and uses thereof
12/25/2003US20030235591 Comprises hepatitis B surface antigens
12/25/2003US20030235590 Hepatitis B virus (hbv) purified in presence of cysteine
12/25/2003US20030235589 Comprises chondroprotective agents, an agent which promotes cartilage anabolic activity, and an agent that inhibits cartilage catabolism; for sustained release; for treatment of neurodegenerative disorders
12/25/2003US20030235588 Thioredoxin (TRX); administering histone deacetylase inhibitors such as trichostatin A; for treating inflammation
12/25/2003US20030235585 Methods of treating disorders in which TFN alpha activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha
12/25/2003US20030235579 Anti-equine Fc epsilon receptor alpha chain antibodies and method to detect IgE
12/25/2003US20030235577 Administration of MMPAP-12 polypeptides and nucleic acids
12/25/2003US20030235576 Based on sodium channel blockers and fibrinolytics
12/25/2003US20030235575 Identification of oligoadenylate synthetase-like genes
12/25/2003US20030235571 Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
12/25/2003US20030235564 Compositions and devices comprising or encoding the Run x2 protein and method of use
12/25/2003US20030235557 Administering two viral vectors containing an immunogenic portion of a wilms' tumor (wt1) polynucleotide operably linked to an expression control sequence
12/25/2003US20030235556 Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein
12/25/2003US20030235536 Administering an aerosol, a conjugate of a therapeutic agent and an FcRn binding partner, for treating resipiratory system disorders, drug delivery of an antibody, immunizing vaccines
12/25/2003US20030235535 Administering a Prokineticin 2 receptor antagonist or agonist; control internal body clock and functions
12/24/2003WO2003107008A2 DIAGNOSTIC POLYMORPHISM OF 11ß-HYDROXYSTEROID DEHYDROGENASE USEFUL FOR IDENTIFYING RISK OF DEVELOPING ALZHEIMER'S DISEASE
12/24/2003WO2003107006A1 Oxaliplatin anti-resistance agent
12/24/2003WO2003107001A1 Method for diagnosing and treating nis-expressing carcinomas and metastases
12/24/2003WO2003106970A2 P27 prevents cellular migration
12/24/2003WO2003106713A1 Antisense modulation of stati expression
12/24/2003WO2003106712A1 Antisense modulation of ptpn12 expression
12/24/2003WO2003106711A1 Antisense modulation of extracellular-signal regulated kinase-6 expression
12/24/2003WO2003106692A2 Methods for the identification of all-antigens and their use for cancer therapy and transplantation
12/24/2003WO2003106681A2 Antisense oligonucleotides against pim1
12/24/2003WO2003106669A1 Purified pkb ser 473 kinase and uses thereof
12/24/2003WO2003106666A2 Protein c variants with altered properties
12/24/2003WO2003106659A2 Aptamer-toxin molecules and methods for using same
12/24/2003WO2003106657A2 Wise/sost nucleic acid sequences and amino acid sequences
12/24/2003WO2003106650A2 Chd5 encoding nucleic acids, polypeptides, antibodies and methods of use thereof
12/24/2003WO2003106648A2 Compositions and methods relating to breast specific genes and proteins
12/24/2003WO2003106647A2 Antisense modulation of junctional adhesion molecule 3 expression
12/24/2003WO2003106646A2 Antisense modulation of dual specific phosphatase 4 expression
12/24/2003WO2003106643A2 Novel polynucleotides encoding lamprey gnrh-iii
12/24/2003WO2003106636A2 Novel methods for the delivery of polynucleotides to cells
12/24/2003WO2003106632A2 Inhibitors of inflammatory gene activity and cholesterol biosynthesis
12/24/2003WO2003106629A2 Treating vitamin d responsive diseases
12/24/2003WO2003106626A2 Method of cell growth inhibition with agnoprotein
12/24/2003WO2003106624A2 Cancer-linked gene as target for chemotherapy
12/24/2003WO2003106619A2 Multifunctional polypeptides
12/24/2003WO2003106618A2 Novel cancer therapies
12/24/2003WO2003106501A1 Fusion protein comprising angiopoietin receptor-binding and a multimerization domain
12/24/2003WO2003106496A1 Antibodies, peptides and vaccines against hiv-1 virus
12/24/2003WO2003106491A2 Cell penetrating peptides
12/24/2003WO2003106489A1 Novel neuropeptide analogs and use thereof
12/24/2003WO2003106488A2 Novel antagonists of cxcr3-binding cxc chemokines
12/24/2003WO2003106487A1 Immunogenic conjugates
12/24/2003WO2003106485A1 Method for the production of protamine
12/24/2003WO2003106483A1 A recombinant anti-enveloped virus peptide and its preparation
12/24/2003WO2003106482A1 Peptides derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions
12/24/2003WO2003106481A1 A process of producing ala-glu dipeptide
12/24/2003WO2003106480A1 Antibacterial amide macrocycles
12/24/2003WO2003106479A2 Pokeweed antiviral protein polypeptides with antiviral activity
12/24/2003WO2003106476A1 Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
12/24/2003WO2003106405A1 Aspartyl protease inhibitors
12/24/2003WO2003105910A1 Metallothionein based neuronal therapeutic and therapeutic methods
12/24/2003WO2003105908A2 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
12/24/2003WO2003105907A2 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
12/24/2003WO2003105901A2 New medical indication
12/24/2003WO2003105900A1 Regulation of secretory phospholipase a2 group iia
12/24/2003WO2003105897A1 Combined use of a modulator of cd3 and a glp-1 compound
12/24/2003WO2003105893A2 Probiotic therapies
12/24/2003WO2003105892A1 Neuroendocrine marker for cancer and method for producing same
12/24/2003WO2003105891A2 Use of hec1 antagonists in the treatment of proliferative disorders and cancer
12/24/2003WO2003105887A1 Inhibition of t cell activation by butyrophilin 4 or b7-l1
12/24/2003WO2003105886A2 Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation
12/24/2003WO2003105885A1 Novel method of screening
12/24/2003WO2003105884A1 Use of shp-1 for the therapy of asthma
12/24/2003WO2003105883A1 Treatment of serious infections and septic shock
12/24/2003WO2003105882A1 Composition comprising viscous fibers and viscosity-lowering proteins
12/24/2003WO2003105881A1 Use of amide derivative of ge 2270 factor a3 for the treatment of acne
12/24/2003WO2003105880A1 Peptides selectively lethal to malignant and transformed mammalian cells
12/24/2003WO2003105879A1 Compositions and methods for preventing, treating and diagnosing diabetes
12/24/2003WO2003105862A1 In-vivo energy depleting strategies for killing drug-resistant cancer cells
12/24/2003WO2003105844A1 Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions
12/24/2003WO2003105835A1 Methods of use for tripeptidyl peptidase ii inhibitors as anticancer agents
12/24/2003WO2003105784A1 Compositions and methods for softening, thinning and removing hyperkeratotic tissue
12/24/2003WO2003105778A2 Phosphatidylinositol-4-phosphate 5-kinase, type ii beta inhibitors for inhibiting angiogenesis
12/24/2003WO2003105777A2 Fiber cell globulization aminopeptidases and methods for treating or preventing cataracts
12/24/2003WO2003105773A2 Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
12/24/2003WO2003105767A2 Antifungal parenteral products
12/24/2003WO2003105763A2 Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
12/24/2003WO2003105760A2 Prevention and treatment of nonalcoholic fatty liver disease (nafld) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (gip)
12/24/2003WO2003105755A2 Antisense modulation of vegf-c expression
12/24/2003WO2003105754A2 Antisense modulation of vegf-b expression
12/24/2003WO2003105753A2 Methods and compositions for grafting functional loops into a protein
12/24/2003WO2003105677A2 Methods for treating viral diseases using modulators of amyloidogenic peptide aggregation
12/24/2003WO2003105676A2 Compositions and methods for reducing lung volume
1 ... 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 ... 3163